Jonsson Comprehensive Cancer Center: Melanoma trials

The registry lists 18 Melanoma studies with Jonsson Comprehensive Cancer Center as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 5Phase 2 7Phase 3 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver MetastasesTerminatedNCT02336763Not applicableResults posted
• Study of Gene Modified Immune Cells in Patients With Advanced MelanomaCompletedNCT00910650Phase 2Results posted
• Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV MelanomaCompletedNCT00471887Phase 2Results posted
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype MelanomaTerminatedNCT04375527Phase 2
• Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1
• PET Imaging of the Immune System Using Analog ProbesCompletedNCT03409419
• Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 MutationsWithdrawnNCT02263898Phase 2
• Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II MelanomaWithdrawnNCT01826864Phase 3
• Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT01005472Phase 1
• Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning AloneCompletedNCT00351728
• Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 BrachytherapyTerminatedNCT00346372
• Cytogenetic Study of Ocular MelanomaCompletedNCT00344799
• Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV MelanomaCompletedNCT00107159Phase 2
• CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With SurgeryCompletedNCT00090896Phase 1
• ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic MelanomaCompletedNCT00081042Phase 2
• Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301Status unknownNCT00070343Not applicable
• Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant MelanomaCompletedNCT00039325Phase 1/2
• Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant MelanomaCompletedNCT00005617Phase 1